55 reports

  • NEURODEGENERATIVE DISORDERS THERAPEUTICS MARKET, COMORBIDITIES ASSOCIATED WITH
  • Dementia
  • World
  • Biogen Idec Inc.
  • Novartis AG
  • Roche Group
  • Alzheimer's Disease Drugs Sales Volume

High blood pressure and anxiety as well as other respiratory problems like asthma, bronchitis, and poor circulation.

  • Dementia
  • China
  • Demand
  • Janssen Biotech, Inc.
  • Xian-Janssen Pharmaceutical Ltd.
  • Alzheimer's Disease Drugs Sales Volume

High blood pressure and anxiety as well as other respiratory problems like asthma, bronchitis, and poor circulation.

  • Dementia
  • China
  • Guizhou Yibai Pharmaceutical Co., Ltd.
  • Novartis AG
  • Shandong Qilu Pharmaceutical Co., Ltd
  • 4.3.4 AZD3293 - ASTRAZENECA

In addition to mild-to-moderate AD, masitinib is being trialed for multiple sclerosis, asthma and various cancers.

  • Dementia
  • Asia
  • World
  • Forecast
  • Biogen Idec Inc.

asthma and chronic obstructive pulmonary disease in Europe February 2014: Receives full approval of SYNRIBO (omacetaxine mepesuccinate) for injection January 2014: The US FDA approves the company' s supplemental NDA for three-times-a-week Copaxone ## mg per ml, a new dose of Copaxone Ja

  • Dementia
  • Biogen Idec Inc.
  • Merck Serono S.A.
  • Novartis AG
  • Pfizer Inc.
  • Alzheimer's Disease Market, Global, AZD3293 Market Forecast ($m), 2019-2021
  • 5.4.4 AB1010 - AB SCIENCE

Besides mild-to-moderate AD, masitinib is being trialed for multiple sclerosis, asthma and various cancers.

  • Dementia
  • World
  • Forecast
  • Market Size
  • Eisai Co., Ltd.
  • PRODUCT PROFILE - AB-1010

AB-## IS CURRENTLY BEING EXPLORED IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA), MULTIPLE SCLEROSIS (MS), ASTHMA, AND SEVERAL TYPES OF CANCERS, IN ADDITION TO BEING INVESTIGATED AN ONGOING PHASE III STUDY IN PATIENTS WITH MILD TO MODERATE AD.

  • Dementia
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Roche Group
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H1 2017
  • Amyotrophic Lateral Sclerosis

Intellectual Property for masitinib is secured in asthma until 2032.

  • Dementia
  • Therapy
  • United States
  • Product Initiative
  • AB Science SA
  • PFIZER INC.

This patent, which expires in 2032 protects to the use of masitinib in the treatment of severe persistent corticosteroid-dependent asthma and severe persistent corticosteroid-resistant asthma.

  • Dementia
  • Therapy
  • United States
  • Product Initiative
  • AB Science SA
  • MASITINIB - DRUG PROFILE

This patent, which expires in 2032 protects to the use of masitinib in the treatment of severe persistent corticosteroid-dependent asthma and severe persistent corticosteroidresistant asthma.

  • Cancer
  • Dementia
  • United States
  • Product Initiative
  • AB Science SA

Neurim offers treatments for other therapeutic areas that include Parkinson" s disease, and asthma or chronic obstructive pulmonary disease.

  • Dementia
  • Neurology
  • United States
  • Product Initiative
  • Flex Pharma, Inc.

DIAGNOSTIC ASSAY - ASTHMA PRODUCT OVERVIEW TABLE ##: DIAGNOSTIC ASSAY - ASTHMA - PRODUCT STATUS TABLE ##: DIAGNOSTIC ASSAY - ASTHMA - PRODUCT DESCRIPTION DIAGNOSTIC ASSAY - CROHN' S DISEASE PRODUCT OVERVIEW TABLE ##: DIAGNOSTIC ASSAY - CROHN' S DISEASE - PRODUCT

  • Chronic Pain
  • Clinical Trial
  • Dementia
  • United States
  • GlobalData's company

ASTHMA PRODUCT OVERVIEW TABLE ##: DIAGNOSTIC ASSAY - ASTHMA - PRODUCT STATUS Cincinnati Children' s Hospital Medical Center (CCHMC) is a healthcare consulting institution that provides children healthcare services.

  • Clinical Trial
  • Dementia
  • Prostate Cancer
  • United States
  • GlobalData's company
  • VERUBECESTAT - DRUG PROFILE

One of these mechanisms, leukotriene signaling, is related to asthma.

  • Dementia
  • United States
  • World
  • Product Initiative
  • Suven Life Sciences Ltd

Presented post approval study results at the American Thoracic Society International Conference that demonstrated the Alair™ Bronchial Thermoplasty System reduced complications, including severe asthma exacerbations and asthma-related hospitalizations, in adult patients with severe

  • Clinical Trial
  • Dementia
  • Pathology
  • Therapy
  • GlobalData's company
  • Cytokinetics, Inc. - Pipeline by Indication, 2015
  • Dementia
  • United States
  • World
  • Product Initiative
  • Cytokinetics, Inc.
  • PIPELINE BY ELI LILLY AND COMPANY, H1 2017
  • PIPELINE BY GENENTECH INC, H1 2017

Its clinical development pipeline includes alectinib and Erlotinib for metastatic non-small cell lung cancer; Anti-ST## for asthma; etrolizumab for ulcerative colitis; atezolizumab for solid tumors and metastatic melanoma; obinutuzumab for non-Hodgkin lymphoma; and pertuzumab for breast canc

  • Dementia
  • Mental Health
  • Research And Development
  • United States
  • Product Initiative

Regeneron is also developing various product candidates in clinical development for treating asthma, pain, cancer, atopic dermatitis and infectious diseases.

  • Chronic Pain
  • Dementia
  • United States
  • Product Initiative
  • Pfizer Inc.
  • MILD COGNITIVE IMPAIRMENT - PIPELINE BY INTELGENX CORP, H2 2017
  • VERUBECESTAT - DRUG PROFILE

One of these mechanisms, leukotriene signaling, is related to asthma.

  • Dementia
  • Pharmaceutical
  • United States
  • Product Initiative
  • Suven Life Sciences Ltd
  • PEPTIDREAM ENTERS INTO DISCOVERY AGREEMENT WITH SANOFI

Its pharmaceutical products comprise inhaled corticosteroid for asthma, osteoporosis drugs, antihyperuricemia agent, and others.

  • Dementia
  • Psychotic Disorder
  • United States
  • Company
  • PeptiDream Inc.
  • Feb 16, 2017: Cytokinetics Reports Fourth Quarter 2016 Financial Results

asthma and chronic obstructive pulmonary disease.

  • Clinical Trial
  • Dementia
  • Pharmaceutical
  • United States
  • Cytokinetics, Inc.

It drugs are used in the treatment of different types of cancer, psoriasis, rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, solid tumors, eye disease, and other inflammatory diseases.

  • Dementia
  • Pharmaceutical
  • United Kingdom
  • Company
  • Heptares Therapeutics Limited
  • AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies

Its clinical development pipeline includes alectinib and Erlotinib for metastatic non-small cell lung cancer; Anti-ST## for asthma; etrolizumab for ulcerative colitis; atezolizumab for solid tumors and metastatic melanoma; obinutuzumab for non- Parent F.

  • Dementia
  • Pharmaceutical
  • United States
  • Product Initiative
  • AC Immune SA
  • PIPELINE BY KYORIN PHARMACEUTICAL CO LTD, H2 2017
  • OCT 11, 2016: MEDICINOVA ANNOUNCES FDA GRANTED ORPHAN DRUG DESIGNATION TO MN-166 (IBUDILAST) FOR AMYOTROPHIC LATERAL SCLEROSIS

IBUDILAST HAS BEEN USED IN ASTHMA AND POST-STROKE DISORDERS IN JAPAN FOR AROUND ## YEARS.

  • Dementia
  • Therapy
  • United States
  • World
  • Product Initiative
  • DEMENTIA - PIPELINE BY WHANIN PHARMACEUTICAL CO LTD, H1 2017
  • DEMENTIA - PIPELINE BY ZHEJIANG HISUN PHARMACEUTICAL CO LTD, H1 2017

WhanIn Pharma' s offers pipeline products under development for the treatment of asthma, stroke, obesity, dementia and Hepatitis C.

  • Dementia
  • United States
  • World
  • Product Initiative
  • Eisai Co., Ltd.
  • PRODUCTS UNDER INVESTIGATION BY UNIVERSITIES/INSTITUTES, H2 2016
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2016

Salk Institute for Biological Studies is investigating CNB-## for the treatment of ischemic stroke, Alzheimer' s disease, Huntington' s disease, Parkinson' s disease, Lung inflammation (asthma) and traumatic brain injury (TBI).

  • Dementia
  • Europe
  • World
  • Product Initiative
  • Phytopharm plc
  • PIPELINE BY GENENTECH INC, H2 2017
  • PIPELINE BY ELI LILLY AND CO, H2 2017

Its clinical development pipeline includes alectinib and Erlotinib for metastatic non-small cell lung cancer; Anti-ST## for asthma; etrolizumab for ulcerative colitis; atezolizumab for solid tumors and metastatic melanoma; obinutuzumab for non-Hodgkin lymphoma; and pertuzumab for breast canc

  • Dementia
  • Mental Health
  • United States
  • Product Initiative
  • Eisai Co., Ltd.
  • NEFLAMAPIMOD - DRUG PROFILE

VX-## has the potential to treat inflammatory diseases such as asthma, Crohn' s disease and rheumatoid arthritis, and neurological diseases such as stroke.

  • Chronic Disease
  • Dementia
  • United States
  • Product Initiative
  • GlaxoSmithKline plc
  • Number of Products under Development by Indications, H2 2017
  • Products under Development by Companies, H2 2017

Ibudilast has been used in asthma and post-stroke disorders in Japan for around ## years.

  • Dementia
  • Therapy
  • United States
  • Product Initiative
  • MediciNova, Inc.
  • Other Developmental Activities

This patent, which expires in 2032 protects to the use of masitinib in the treatment of severe persistent corticosteroid-dependent asthma and severe persistent corticosteroid-resistant asthma.

  • Dementia
  • Hospital
  • In Vitro Diagnostic Reagent
  • Lung Cancer
  • AB Science SA